Navigation Links
NeoStem Raises $5 Million in Registered Direct Offering
Date:6/25/2010

or to registration or qualification under the securities laws of any such state or jurisdiction.

About NeoStem, Inc.

NeoStem, Inc. is engaged in the development of stem cell-based therapies, pursuit of anti-aging initiatives and building of a network of adult stem cell collection centers in the U.S. and China that enable people to donate and store their own (autologous) stem cells for potential personal use in times of future medical need. The Company is also the licensee of various stem cell technologies, including a worldwide exclusive license to VSEL(TM) Technology, which uses very small embryonic-like stem cells shown to have several physical characteristics that are generally found in embryonic stem cells, and is pursuing the licensing of other technologies for therapeutic use. NeoStem's majority-controlled Chinese pharmaceutical operation, Suzhou Erye, manufactures and distributes generic antibiotics in China. For more information, please visit: http://www.neostem.com .

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the success of lab construction, new stem cell projects and new pharmaceutical development and licensing, about which no assurances can be given. The Company's actual results could differ materially f
'/>"/>

SOURCE NeoStem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NeoStem Selected to Present at American Society for Apheresis
2. NeoStems Advanced Adult Stem Cell Technology to be Featured at Upcoming Conference
3. NeoStem to Ring Opening Bell at New York Stock Exchange on May 27, 2010
4. NeoStem Announces Conversion of Convertible Preferred Stock by Principal Shareholder
5. NeoStem Provides Update on its Pharmaceutical Subsidiary Suzhou Erye
6. NeoStem, Inc. to Present at NASDAQ MarketSite
7. NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
8. NeoStem Appoints Deloitte & Touche as New Independent Registered Public Accounting Firm
9. NeoStem Announces Presentation Time Change at Roth Capital Partners 22nd Annual OC Growth Stock Conference
10. NeoStem Enters into SRA with University of Michigan; Funding from NIH Stem Cell Research Grant
11. NeoStem Prices Public Offering of 5,000,000 Shares of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2015)... YORK and MUMBAI, India ... (BSE: 532540, NSE: TCS) a leading global IT services, ... been designated as a Leader in Worldwide Life Sciences ... in the " IDC MarketScape: Worldwide Life Science R&D ... report. The report evaluated eight leading ...
(Date:6/26/2015)... ... ... ReliantHeart, Inc. , an innovative supplier of advanced mechanical circulatory assist technologies ... (HA5) to the 68th consecutive implant, there has been no evidence of de novo ... referred to as de novo thrombus. De novo thrombus can hide under the impeller ...
(Date:6/25/2015)... Rowley, MA (PRWEB) , ... June 25, 2015 ... ... fall at Framingham State University will enjoy (8) new chemistry laboratories, each exclusively ... , Last week, Erlab’s team finished installing the (49) filtered fume hoods needed ...
(Date:6/25/2015)... - Portage Biotech Inc. ("Portage" or "the Company") (Canadian ... pleased to announce that it has completed its non-brokered ... million common shares at US$0.14 each. The private placement ... June 15, 2015 as per our press release of ... on June 24, 2015. The Company is debt free. ...
Breaking Biology Technology:TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 2TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 3TCS Recognized as a Leader in Life Sciences R&D Risk-Based Monitoring by IDC MarketScape 4HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 2HeartAssist5® Remote Monitoring has alerted no patterns of de novo thrombus in 68 consecutive implants 3This Summer Erlab Completes the Largest Installation of Filtered Fume Hoods in the World 2Portage Completes Non-brokered Private Placement in Two Tranches for a Total Proceeds of US$ 5,155,080 2Portage Completes Non-brokered Private Placement in Two Tranches for a Total Proceeds of US$ 5,155,080 3
... Companies will Present at the Largest Marketplace for Emerging ... and CTSI today announced that more than 100 leading ... partners will be showcased in the 4th Annual TechConnect ... R. Brown Convention Center in Houston, Texas. Held ...
... Development and InnovationMOUNTAIN VIEW, Calif., April 22 ... Pharmaceuticals & Biotechnology group assesses a variety of ... in cancer treatment. Physicians, nurses and patients ... reconstitution, home vs. office administration parameters, and barriers ...
... 22 GeneGo, Inc., a leading provider of software ... , today announced that the University of Cardiff has ... researchers will have access to GeneGo,s MetaCore, training and ... their partner relationship with GeneGo to provide a pathway ...
Cached Biology Technology:TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 2TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 3TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 4Frost & Sullivan: Female Cancer Patients More Willing to Use Implantable Infusion Pumps Than Males 2Frost & Sullivan: Female Cancer Patients More Willing to Use Implantable Infusion Pumps Than Males 3Cardiff University Becomes a GeneGo Center of Excellence 2
(Date:6/25/2015)... N.J. , June 25, 2015  TAKE Solutions ... a patent by the United States Patent and Trademark ... Standardization". This process leverages TAKE Solutions, Clinical Accelerators to ... over 50% (when compared to standardization without the accelerators), ... At the heart of ...
(Date:6/24/2015)... 2015 This report provides market analysis of ... years. It contains an analysis of the drivers, challenges, ... impact from the short, medium, and long term perspective ... market, and technology trends that currently, prevail in the ... authorities to efficiently manage the increasing marine traffic and ...
(Date:6/24/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/hhwlfj/huawei_ascend ... "Huawei Ascend Mate 7 Fingerprint Sensor - Reverse ... Huawei,s technological choice for the fingerprint sensor ... and Samsung,s one. The Ascend Mate 7 presents ... a main actor in capacitive sensing human interface ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... Jos Zanchetta, a member of the IOF Board and ... has been named the recipient of the prestigious Pierre ... Osteoporosis Foundation (IOF) in memory of Pierre D. Delmas, ... growth of the Foundation and osteoporosis advocacy worldwide. ...
... the damage caused by a heart attack survived in the ... a mouse model, researchers at The University of Texas MD ... Circulation Research . The study, with researchers at the ... imaging techniques developed by researchers at MD Anderson to track ...
... a 1600 km-wide ash cloud over the Atlantic. The ... visible in stark contrast to white clouds framing this ... emitting steam and ash on 20 March, wreaking havoc ... week caused some flights to be suspended to and ...
Cached Biology News:Transplanted adult stem cells provide lasting help to injured hearts 2Transplanted adult stem cells provide lasting help to injured hearts 3Transplanted adult stem cells provide lasting help to injured hearts 4
...
cysteine and glycine-rich protein 2,...
... agent and DNA-topoisomersae II inhibitor (IC50 = 59.2 ... C 29 H 32 O 13 ... Store at: RT ... Soluble to 100 mM ...
HSPBP1 Antibody...
Biology Products: